Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.
Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
Funding Rounds (5) - $61.5MUpdate
Current Team (6)Update
|Jul 19, 2016||The Street - Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact|
|Jun 19, 2016||Xconomy - Epizyme Touts Early Data From Key Trial Of Blood Cancer Drug|
|May 2, 2016||Business Wire - Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences|
|Apr 15, 2016||PRNewswire UK All - The Companion Diagnostics (CDX) Market Forecast 2016-2026|
|Mar 24, 2016||PRWeb Sitemap - Cancer Advance Boston Joins Leading Oncology Experts for a Networking Conference on April 4th and 5th|
|Mar 9, 2016||Business Wire - Epizyme Announces 2015 Financial Results and Financial Guidance|
|Mar 3, 2016||Xconomy - Stealthy MIT Spinout Ribon, Led by a Sanofi Vet, Takes Aim at Cancer|
|Mar 2, 2016||Business Wire - Epizyme to Report 2015 Financial Results and Provide Business Updates on March 9, 2016|